NYSE$UTZ

Utz Brands Inc · Q4 2023 earnings

Q4 2023 earnings · · Investor relations

Briefing

Utz's Q4 2023 results reflected a slight decrease in net sales, but adjusted EBITDA increased.

Utz Brands reported a decrease in net sales by 0.7% to $352.1 million for Q4 2023. However, adjusted EBITDA increased by 12.0% to $49.4 million. The company experienced a net loss of $(33.2) million compared to a net income of $13.8 million in the prior year period.

  • Net sales decreased (0.7)% year-over-year to $352.1 million.
  • Organic Net Sales decreased (0.3)% year-over-year.
  • Net loss of $(33.2) million vs. net income of $13.8 million in the year-ago period.
  • Adjusted EBITDA increased 12.0% year-over-year to $49.4 million.

Headline financials

Total Revenue

$352M

Previous: $355M-0.7%
EPS (adj)

$0.16

Previous: $0.15+6.7%
Organic Net Sales Growth

-0.3%

No prior period
Adjusted EBITDA Margin

14.0%

Previous: 12.4%+12.9%
Capital Expenditures

-$10M

Previous: $13.9M-171.8%
Net Income

-$33.2M

Previous: -$7.75M-328.6%
Operating Income

$10.2M

Previous: -$5.98M+270.3%
Gross Profit

$115M

Previous: $90.5M+27.5%
Stock-Based Comp

$5.26M

Previous: $4.28M+22.9%

Revenue & EPS history

Utz · Revenue · Quarterly

$352M

Q4 2023-0.7%vs Q4 2022
Beat estimate in 11 of 15 quarters(73%)
ActualEstimate

Forward guidance

In fiscal 2024, the Company expects organic net sales growth of ~3% or better driven by volume growth, and assumes total net sales to be impacted by ~$45 million due to the recently closed transaction for the dispositions of the Good Health® and R.W. Garcia® brands and manufacturing facilities. Adjusted EBITDA growth of 5% to 8% and Adjusted EPS growth of 16% to 21%.

Tailwinds

  • Organic Net Sales growth of ~3% or better driven by volume growth.
  • Adjusted EBITDA growth of 5% to 8%.
  • Adjusted EPS growth of 16% to 21%.
  • Effective tax rate (normalized GAAP basis tax expense, which excludes one-time items) in the range of 19% to 21%.
  • Net Leverage Ratio of ~3.6x at year-end fiscal 2024.

Headwinds

  • Total net sales to be impacted by ~$45 million due to the recently closed transaction for the dispositions of the Good Health® and R.W. Garcia® brands and manufacturing facilities.
  • Assumes the estimated impact of the forgone contribution to Adjusted EBITDA from the brand dispositions are mostly offset by accelerated cost savings and the transition services agreement.
  • Interest expense of ~$50 million.
  • Capital expenditures in the range of $80 to $90 million.
  • A quantitative reconciliation is not available without unreasonable efforts due to the high variability, complexity, and low visibility with respect to certain items which are excluded from Adjusted EBITDA.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q4 2023

Historical avgQ4 2023

-0.2%

Avg return

Earnings day

+0.1%

Avg return

5 days after

-1.1%

Avg return

30 days after

55%

12 / 22 earnings

Positive

+15.2%

Q1 2022

Best reaction

-13.4%

Q3 2025

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+2.8%-6.2%-8.1%
Q4 2025-4.8%+2.9%-19.2%
Q3 2025-13.4%-15.4%-18.9%
Q1 2025-8.7%-8.8%-0.5%
Q4 2024+2.8%+5.0%+1.9%
Q3 2024+7.0%+6.3%+7.4%
Q2 2024+9.5%+12.5%+13.8%
Q1 2024+6.1%+4.6%+2.3%
Q4 2023-4.5%-4.0%+0.5%
Q3 2023+1.1%+6.6%+11.5%
Q2 2023+2.3%-1.3%-10.9%
Q1 2023-7.3%-5.4%-13.9%
Q4 2022+5.1%+6.6%+1.0%
Q3 2022+5.4%+8.2%+11.7%
Q2 2022-4.5%-4.3%-9.8%
Q1 2022+15.2%+14.2%+4.1%
Q4 2021-8.9%-3.0%+4.0%
Q3 2021+8.4%+7.2%+0.1%
Q2 2021-9.9%-13.6%-7.2%
Q1 2021-7.1%-8.2%-6.4%
Q3 2020-0.3%-2.1%+12.1%
Q4 2019+0.1%-0.1%+0.2%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro